2025年12月期 第１四半期決算短信〔ＩＦＲＳ〕（連結）

This document presents the first quarter financial results for the fiscal year ending December 2025 of GNI Group, Inc. The consolidated performance from January 1 to March 31, 2025, shows revenue of 5,320 million yen, an operating loss of 772 million yen, and a quarterly loss of 1,266 million yen, reflecting a 10.6% decrease in revenue compared to the same period last year. The company faces uncertainties in the economic environment and geopolitical risks. Despite these challenges, GNI Group continues its commitment to innovative pharmaceutical research and development, with expectations for new drug sales, particularly in the rare disease sector.